Department of Cardiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Biomed Res Int. 2020 Jan 17;2020:2018035. doi: 10.1155/2020/2018035. eCollection 2020.
The use of a large number of cardiovascular biomarkers, meant to complement the use of the electrocardiogram, echocardiography cardiac imaging, and clinical symptom assessment, has become a routine in clinical diagnosis, differential diagnosis, risk stratification, and prognosis and guides the management of patients with suspected cardiovascular diseases. There is a broad consensus that cardiac troponin and natriuretic peptides are the preferred biomarkers in clinical practice for the diagnosis of the acute coronary syndrome and heart failure, respectively, while the roles and possible clinical applications of several other potential biomarkers are still under study. This review mainly focuses on the recent studies of the roles and clinical applications of troponin and natriuretic peptides, which seem to be the best-validated markers in distinguishing and predicting the future cardiac events of patients with suspected cardiovascular diseases. Additionally, the review briefly discusses some of the large number of potential markers that may play a more prominent role in the future.
大量心血管生物标志物的应用，旨在补充心电图、超声心动图心脏成像和临床症状评估的使用，已成为临床诊断、鉴别诊断、风险分层和预后的常规方法，并指导疑似心血管疾病患者的管理。人们广泛认为，肌钙蛋白和利钠肽分别是临床实践中诊断急性冠状动脉综合征和心力衰竭的首选生物标志物，而其他几种潜在生物标志物的作用和可能的临床应用仍在研究中。本综述主要关注肌钙蛋白和利钠肽的作用和临床应用的最新研究，这两种标志物似乎是鉴别和预测疑似心血管疾病患者未来心脏事件的最佳验证标志物。此外，该综述还简要讨论了一些未来可能发挥更重要作用的大量潜在标志物。
